^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TMB-H + PD-L1 overexpression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, TMB | Tumor Mutational Burden
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over3years
    [VIRTUAL] Landscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology (IO) biomarkers. (ASCO 2021)
    Background: Sotorasib has shown promising activity in cancer patients (pts) specifically harboring the KRASG12C mutation... Our data suggest that KRAS variants significantly differ by cancer type . Tumors harboring KRASG12C were significantly associated with high TMB and PD-L1 overexpression . KRASG12C mutation appeared to be associated with smoking status .
    Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • STK11 (Serine/threonine kinase 11) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMAD4 (SMAD family member 4)
    |
    BRAF V600E • KRAS mutation • TMB-H • MSI-H/dMMR • PD-L1 overexpression • KRAS G12C • KRAS G12D • KRAS G12V • KEAP1 mutation • KRAS G12 • KRAS G13 • TMB-H + PD-L1 overexpression • KRAS overexpression
    |
    Tempus xT Assay • Tempus xF Assay
    |
    Lumakras (sotorasib)